MINING The Boulle Mining Group (''BMG'') is a division of the Jean Boulle Group which over the years has discovered some of the largest mineral resources projects in the world. KNOW MORE MEDTECH Jean Boulle Medtech Ltd. is active in a wide range of pioneering and lifesaving medical technologies KNOW MORE THERAPEUTICS Boulle Therapeutics identifies, invests in, and supports innovations that have the potential to save lives and improve the quality of life for large numbers of people KNOW MORE AGRICULTURE The Jean Boulle Group's Indian Ocean Fields Ltd. is one of the largest shareholders of Omnicane Limited, a leading producer of sugarcane and power generation in Mauritius KNOW MORE LUXURY PRODUCTS The Jean Boulle Group has more than 50 years’ experience in all facets of the diamond industry: mining, sourcing, purchasing, cutting and polishing high-quality natural diamonds. KNOW MORE


The Jean Boulle Group acquires promising assets and projects and optimizes their structure, management and development with private and public investment.


Trained Therapeutix Discovery appoints Nobel Laureate Dr. James Allison, Dr. Padmanee Sharma, and Dr. Mihai Netea to its Scientific Advisory Board

19th April, 2021
Trained Therapeutix Discovery (“TTxD”) announces that it has extended its Scientific Advisory Board to include James P. Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D. Dr. Allison received the 2018 Nobel Prize in Physiology or Medicine for his work on discovering immune checkpoint blockade and is the Regental Professor and Chair of the Department of Immunology, the Olga Keith Wiess Distinguished University Chair for Cancer Research, Director of the Parker Institute for Cancer Research, and the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. Dr. Sharma is a pioneer and world-renowned expert in designing and running immuno-oncology clinical trials and is a practicing immunologist and oncologist at MD Anderson Cancer Center. [...]

Jean Boulle Joins Board of Corporate Council on Africa

Luxembourg, 22 February 2021
The Jean Boulle Group (“the Group”) is pleased to confirm the appointment of Jean-Raymond Boulle to the Board of the Corporate Council on Africa (“CCA”). [...]

Jean Boulle Medtech company VDYNE obtains significant investment from a large global medical device company to close $21 million financing for human trials of ground breaking transfemoral tricuspid heart valve replacement technology

6 January, 2021
Jean Boulle Medtech Ltd is pleased to announce that VDYNE, Inc. ("VDYNE" or “the Company”), a privately held medical device company founded by Jean Boulle Medtech to develop a transcatheter replacement tricuspid valve, has closed a $21 million, heavily subscribed Series C financing. 

25B Boulevard Royal
L2449 Luxembourg
Grand Duchy Luxembourg

Tel: +352 222 512
Fax: +352 222 413

Copyright © 2019 Jean Boulle Group. All rights reserved.